O ne of the challenges facing the surgeon performing reconstruction after bone sarcoma resection in the preadolescent patient is the paucity of data describing long-term outcomes. However, the current study by Staals and colleagues will add to our knowledge, thanks to an impressive 9-year mean followup period.
The study authors observed 15 patients with a mean age of 8 years. They were able to follow 10 long-term survivors for a mean of 104 months, making their paper the longest-term study of these types of implants of which I am aware. Still, with decades of life ahead for survivors of pediatric cancers, it is clear that surgeons and patients will face unanticipated challenges in the years ahead.
The arrival of a prosthesis that can be lengthened inside the body of a pediatric patient without an invasive surgical procedure was an exciting advance [9] . After an enthusiastic adoption by many centers, there have now been several reports of mechanical and aseptic failure of these implants; in addition to the authors of the current study, others have also reported breakage of the embedded spring mechanism responsible for the implant's extensibility [1, 6] . In retrospect, this should not be surprising as the implant relied on a deformable plastic locking ring to hold the implant length constant between expansions. Lengthening is performed by application of an external electromagnetic field that warms and softens this plastic ring and allows the spring to extend the implant. However, this also means that the child loads the same plastic ring with every step. A material design which may be adequate for a small 7-year-old, may not last long in that child after 3 years of growth.
Somewhat less expected was the high rate of aseptic stem loosening. In one paper [2] , this caused nearly half of the failures requiring revision. In contrast, the authors of this manuscript ascribed only one of 10 revisions to aseptic loosening. However, they reported the use of supplementary allograft in five of their 10 revisions for severe bone loss. In most large series of (adult) modular endoprosthetic reconstructions, an aseptic loosening rate of 10% to 15% is a relatively consistent finding. With the expected enlargement of the femoral canal diameter and higher activity levels in the pediatric population, we may yet find higher rates of loosening once we are able to prevent other modes of earlier failure.
Where Do We Need To Go?
Clearly, one consistent challenge is engineering a device that provides reliable expandability while remaining durable in the face of an active adolescent. In the United States, two manufacturers (Stryker, Mahwah NJ, USA and Biomet, Warsaw IN, USA) offer FDA-cleared expandable femoral devices that are lengthened via minor surgical procedures. Several years ago, an implant design that could be lengthened noninvasively was developed in the UK [4, 8] and is sold in the United States by Stanmore Worldwide (Hertfordshire, UK). These designs feature in common a solid metal worm-screw type expansion mechanism which will almost certainly prove to be more durable than the hybrid metal-plastic mechanism in the Repiphysis 1 implant.
Any pediatric endoprosthesis will also have to remain well fixed despite changes in the dimensions of the child's bones. In this respect, implant fixation via osseointegration, for example such as currently offered by the Compress TM implant (Biomet, Warsaw, IN, USA), may turn out to be a more promising alternative to diaphyseal stem fixation in pediatric patients [5] .
How Do We Get There?
In addition to the bioengineering challenges described above, we also need to define our treatment goals more clearly. In the rapidly growing pediatric patient, can an endoprosthesis reasonably be expected to last until skeletal maturity? Staals and colleagues reported that ''only'' three of 10 patients were able to be revised directly to an adult type megaprosthesis. While we all strive for ''success'' rates higher than 30%, we also should counsel our younger patients' families that they may well undergo one or more implant revisions before reaching skeletal maturity. We also have to determine as a specialty the ideal ages for pediatric reconstruction with extendible implants. One long-term study [7] shows that the risk of complications increases with younger age, yet the advantage of limb sparing surgery compared to amputation in terms of quality of life is less certain in these younger patients. Reports such as the study by Staals and colleagues add to our understanding of the extent of these complications.
A more systematic approach to predicting limb length inequality in the setting of endoprosthetic reconstruction will help us plan for converting these implants to nonextendible adult endoprosthesis [3] . Some adolescents may be spared a revision procedure if we accept some permanent limb length inequality, perhaps mitigated by lengthening of the limb at the time of the final surgery. Given evolving technologies, we may also need to be creative in problem-solving on behalf of our patients. For example, in my practice, I would percutaneously inject cement into the spring mechanism of these implants when they began to fail, ''freezing'' them in position. This might allow the patient 12 months to 18 months more usage before continued growth of the other limb requires revision, either to an adult prosthesis or to another expandable implant. Like the authors, however, I have also abandoned this type of implant due to the associated complications.
Finally, as the authors noted, initial reports on the short-term results of this implant were positive, but there have been increasing concerns about the high complication rate and poor function at longer followup. Articles like this one reinforce the need for a national joint replacement registry so that implant problems are more widely apparent earlier.
